Sanifit Therapeutics, a Spain-based developer of treatments for vascular calcification disorders spun out of University of the Balearic Islands, has been bought by pharmaceutical group Vifor Pharma for €205m ($231m) upfront that could be expanded by up to €170m in clinical, regulatory and market access milestone payments. Sanifit had raised $149m as of a $62.8m series D round in mid-2019 featuring pharmaceutical firm Lundbeck vehicle Lundbeckfonden Ventures.

Forendo Pharma, a Finland-based endometriosis drug developer backed by Karolinska Development, the commercialisation…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email Linked in